Methods and compositions for preventing a condition

Abstract

Provided herein are methods, compositions, and kits for preventing, inhibiting, reducing the severity of, or treating a disease or condition. A pharmaceutical composition provided herein can comprise a nucleic acid sequence encoding an antigen fused to an immune cell product, e.g., MIP-3α, and an adjuvant. The antigen can be from a bacteria, virus, fungus, parasite, or cancer. The antigen can be an Alzheimer's disease antigen.

1 .- 98 . (canceled) 
     
     
         99 . A method, comprising:
 administering to a subject having a cancer a nucleic acid encoding a fusion protein, wherein the fusion protein comprises a cancer antigen fused to human macrophage inflammatory protein-3 alpha (MIP-3α);   administering to the subject a CpG oligodeoxynucleotide; and   administering to the subject interferon alpha (IFN-α) or a nucleic acid encoding IFN-α.   
     
     
         100 . The method of  claim 99 , wherein the cancer antigen is a melanoma antigen. 
     
     
         101 . The method of  claim 100 , wherein the melanoma antigen is gp100. 
     
     
         102 . The method of  claim 99 , wherein the nucleic acid is a deoxyribonucleic acid (DNA). 
     
     
         103 . The method of  claim 102 , wherein the DNA is a plasmid DNA. 
     
     
         104 . The method of  claim 99 , wherein the subject is a human subject. 
     
     
         105 . A method, comprising:
 administering to a subject having a cancer a nucleic acid encoding a fusion protein, wherein the fusion protein comprises a cancer antigen fused to human macrophage inflammatory protein-3 alpha (MIP-3α);   administering to the subject a CpG oligodeoxynucleotide; and   administering to the subject a cytokine or a nucleic acid encoding a cytokine.   
     
     
         106 . The method of  claim 105 , wherein the cancer antigen is a melanoma antigen. 
     
     
         107 . The method of  claim 106 , wherein the melanoma antigen is gp100. 
     
     
         108 . The method of  claim 105 , wherein the nucleic acid is a deoxyribonucleic acid (DNA). 
     
     
         109 . The method of  claim 108 , wherein the DNA is a plasmid DNA. 
     
     
         110 . The method of  claim 105 , wherein the cytokine is an interferon. 
     
     
         111 . The method of  claim 105 , wherein the subject is a human subject. 
     
     
         112 . A method, comprising:
 administering to a human subject having a cancer a deoxyribonucleic acid (DNA) encoding a fusion protein, wherein the fusion protein comprises gp100 fused to human macrophage inflammatory protein-3 alpha (MIP-3α);   administering to the subject a CpG oligodeoxynucleotide; and   administering to the subject interferon alpha (IFN-α) or a nucleic acid encoding IFN-α.